NOT (NOT) News
Follow NOT (NOT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 89 public stories across 21 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
US FDA expands Novartis drug use for chronic itchy welts
The US FDA expanded use of Novartis’ BX:NOT drug to treat adults with symptomatic dermographism, a chronic skin condition causing recurring itchy welts, the Swiss drugmaker said.
REGULATION | Oct 07, 2026, 04:39 PM UTC
H
Novartis Licenses Drug Candidate From Abogen for Up to $7.8 Billion
Swiss drugmaker Novartis has struck a deal valued at up to $7.8 billion to license a drug candidate from China's Abogen Biosciences, including an upfront payment of $575 million and options over future therapies. This pa
EQUITY | Oct 02, 2026, 10:35 AM UTC
M
Novartis strikes $7.8 billion mRNA deal with China's Abogen
Swiss drug maker Novartis has signed a licensing and option agreement with Chinese biotech firm Abogen worth approximately $7.8 billion to advance RNA-based therapy.
EQUITY | Oct 02, 2026, 07:58 AM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
ChrysCap, Tata Cap Fund III Invest $70m in Linux Labs
Tata Capital Healthcare Fund II MAKES COMPLETE EXIT Our Bureau Mumbai: Drug maker Linux Laboratories said on Tuesday that it secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. C
MNA | Sep 30, 2026, 04:17 AM UTC
L
Pharma sector doubles down on AI to slash costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency across their pipelines.Industry
NEWS | Sep 29, 2026, 01:35 PM UTC
H
Weekly Recap: Novartis $30B market loss and CEO sees midterm sales growth
Novartis AG (USD) (NYSE:NVS) plunged about $30 billion in market value after disappointing trial results, prompting a major shareholder to slam its M&A strategy even as the CEO projects midterm sales growth from upcoming
EARNINGS | Sep 28, 2026, 11:04 AM UTC
H
Weekly Recap: Guidance extension to 2031 and remibrutinib Phase III success
Novartis AG (SIX:NOVN) navigates a mixed outlook: CEO Vas Narasimhan expects faster sales growth and may extend guidance, while clinical wins for remibrutinib and a positive Cosentyx opinion contrast with late—stage setb
EARNINGS | Sep 28, 2026, 05:01 AM UTC
L
Novartis defeats drug-purchaser lawsuit over delay of Entresto generics
By Blake BrittainA federal judge in Manhattan ruled for Novartis BX:NOT on Wednesday against allegations that it misused one of its patents to maintain its exclusivity on its blockbuster heart-failure drug Entresto.US Di
REGULATION | Sep 23, 2026, 06:59 PM UTC
L
RBC says AI weakness appears to be fueling biotech rally
RBC SAYS AI WEAKNESS APPEARS TO BE FUELING BIOTECH RALLYWeakness in artificial intelligence-related stocks may be helping fuel a biotech rally as investors shift money from volatile technology shares into healthcare stoc
EQUITY | Sep 23, 2026, 01:15 PM UTC
M
Celldex drug meets goals in two late-stage trials
Celldex Therapeutics said its experimental drug for a skin disease met the main and secondary goals in two late-stage trials.
EQUITY | Sep 22, 2026, 11:38 AM UTC
M
Novartis Says EMA CHMP Gives Positive Opinion for Cosentyx
Novartis said the EMA CHMP adopted a positive opinion recommending marketing authorization for Cosentyx.
REGULATION | Sep 18, 2026, 03:00 PM UTC
M
Novartis gets positive CHMP opinion for Cosentyx in PMR
REGULATION | Sep 18, 2026, 02:51 PM UTC
M
Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental amyotrophic lateral sclerosis drug after a mid-stage study failed to meet its goals.
EQUITY | Sep 16, 2026, 04:51 PM UTC
M
Novartis discontinues Phase 2 ALS trial after failed endpoints
Novartis said its Phase 2 ALS treatment VHB937 did not meet primary or secondary endpoints and the company will discontinue development.
EARNINGS | Sep 16, 2026, 03:52 PM UTC
M
Novartis discontinues ALS drug trial after failure
Bloomberg News reports Novartis discontinued development of an experimental ALS medicine after a mid-stage trial failed to show it worked better than a dummy drug in delaying disease.
EQUITY | Sep 16, 2026, 03:14 PM UTC
M
Legend Biotech names Ingrid Zhang CEO
Legend Biotech (LEGN) appointed Ingrid Zhang as chief executive on Tuesday, ending a two-month search after former CEO Ying Huang resigned in July.
EQUITY | Sep 15, 2026, 11:40 PM UTC
L
350% rally in 3 years, multibagger pharma stock to be in focus on Wednesday | Key details from filing
New Delhi, Sept. 15 -- Shares of Sudarshan Pharma Industries are likely to attract investors' interest on Wednesday, September 16, after the company said the proposal to acquire a 9.50% equity stake in MedTherapy Biotech
MNA | Sep 15, 2026, 04:05 PM UTC
L
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech NASDAQ:LEGN on Tuesday appointed longtime Novartis BX:NOT executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy C
NEWS | Sep 15, 2026, 12:43 PM UTC
L
HBA India Summit Calls For Leaders To Command The AI Shift
Hyderabad summit highlights AI, GCCs, commercial acumen and influence as India takes on a larger role in global healthcare leadershipThe Healthcare Businesswomen’s Association (HBA) India hosted the third edition of its
NEWS | Sep 15, 2026, 08:32 AM UTC
H
Weekly Recap: Trial failures and ~10% share drop, weaker 2030s outlook
Novartis AG (SIX:NOVN) shares plunged after late—stage failures for neuromuscular del—desiran and a cholesterol candidate, prompting analyst downgrades and price—target cuts, even as the company keeps 2025—30 sales guida
EARNINGS | Sep 14, 2026, 05:15 AM UTC
L
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street — WSJ
By David WainerThere is a strange paradox haunting healthcare investing right now.Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.Th
NEWS | Sep 12, 2026, 09:30 AM UTC
L
Novartis: More Pain on the Way? — Barrons.com
Can it get any worse for Novartis' U.S. stock?The Swiss company said Tuesday that del-desiran, part of a recent acquisition, reached the end of the line in a trial for a rare neuromuscular disease. Last week, another, pe
MNA | Sep 11, 2026, 10:42 PM UTC
L
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis NYSE:NVS, the global innovative-medicines company, confronted sharper questions over its dealmaking strategy Friday after clinical setbacks weakened confidence in recent acquisitions. Its U.S.-listed shares trad
EQUITY | Sep 11, 2026, 08:01 PM UTC
L
Novartis facing board change threat from shareholder following trial failures
A large Novartis NYSE:NVS shareholder is calling for changes on the Swiss pharma giant's board in the aftermath of two phase 3 drug trial setbacks in the last few weeks.Artisan Partners Managing Director David Samra told
MNA | Sep 10, 2026, 02:33 PM UTC
L
HSBC raises Novartis price target to $136 from $123
EQUITY | Sep 10, 2026, 02:26 PM UTC
M
Novartis shareholder calls for board shake-up after trial setbacks
A major shareholder in Novartis called for changes to the Swiss drugmaker’s board to improve corporate governance. The appeal follows back-to-back trial setbacks and a record share fall this week.
EQUITY | Sep 10, 2026, 10:20 AM UTC
L
Novartis not to rush ahead of upcoming patent expirations, RBC says
RBC Capital Markets analysts say Novartis shouldn’t rush to cover upcoming patent expirations, arguing recent clinical-trial setbacks require bringing the rest of its pipeline to market with a high standard and possibly
EQUITY | Sep 09, 2026, 03:07 PM UTC
L
Citi says Novartis selloff on neuromuscular trial failure looks overdone
Citi analysts said Novartis’s stock selloff following a neuromuscular drug clinical-trial failure looks overdone. They added the company reiterated its 2025-2030 outlook and noted upcoming study results could be more pos
EQUITY | Sep 09, 2026, 08:24 AM UTC
L
Novartis trial setback seen widening early-2030s sales gap
Deutsche Bank’s Emmanuel Papadakis says Novartis’s latest clinical-trial setback raises questions about its acquisition track record and points to a sales hole to be plugged in the early 2030s.
EARNINGS | Sep 09, 2026, 08:01 AM UTC
L
Novartis cut to Hold from Buy by Deutsche Bank
Novartis rating cut to Hold from Buy by Deutsche Bank.
EQUITY | Sep 09, 2026, 06:25 AM UTC
L
Novartis target started at CHF120 by RBC
RBC started coverage with a CHF120 target for Novartis.
EQUITY | Sep 09, 2026, 06:17 AM UTC
L
Novartis Started at Sector Perform by RBC
Novartis Started at Sector Perform by RBC
EQUITY | Sep 09, 2026, 06:16 AM UTC
M
Novartis shares tumble after del-desiran trial fails, worst day in 20+ years
Novartis (NVS) shares slid 14% after a late-stage study of del-desiran in myotonic dystrophy type 1 failed its primary test, the second failed trial in a week.
EQUITY | Sep 08, 2026, 08:09 PM UTC
M
Swiss SMI falls after heavy selling at Novartis
Switzerland’s SMI ended down 221.77 points (1.55%) at 14,057.61 after heavy selling at Novartis, according to TradingView News.
EQUITY | Sep 08, 2026, 06:06 PM UTC
M
Dyne and Sarepta shares slump as Novartis trial setback hits muscle disease stocks
Shares of Dyne Therapeutics (DYN) and Sarepta (SRPT) fell Tuesday after Novartis’ NOT treatment for a muscle-wasting disorder failed in a trial, raising concerns about similar therapies for a rare disease.
EQUITY | Sep 08, 2026, 05:00 PM UTC
M
Novartis shares slide after third clinical setback
Novartis’ U.S.-listed stock was pacing toward its steepest drop on record after the company announced its third clinical setback in a matter of days.
EQUITY | Sep 08, 2026, 12:57 PM UTC
M
Novartis shares tumble after second late-stage drug setback
Novartis shares fell after the company reported a second late-stage clinical setback. Its global Phase III HARBOR study in myotonic dystrophy type 1 (DM1) did not demonstrate a statistic.
EQUITY | Sep 08, 2026, 11:39 AM UTC
H
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market — Barrons.com
By George GloverStock futures were dropping on Tuesday as oil prices neared $100 a barrel, bolstering the case for the Federal Reserve to hike interest rates next week.Artificial-intelligence stocks were rising despite t
MACRO | Sep 08, 2026, 11:06 AM UTC
L
WSJ cites Novartis setback as warning for pharma M&A
TradingView/WSJ says Novartis’ latest trial setback is being framed as a cautionary tale for investors betting on big pharma’s strategy of bite-size acquisitions to support drug pipelines.
MNA | Sep 08, 2026, 10:47 AM UTC
L
Novartis may need more deals after neuromuscular trial failure
Jefferies says Novartis’s latest clinical-trial failure points to a need for more dealmaking to deliver steady growth beyond 2030, while the company maintained its 2025-30 sales guidance.
EARNINGS | Sep 08, 2026, 08:17 AM UTC
M
Novartis trial setback: del-desiran fails late-stage main goal
Novartis said del-desiran, an experimental treatment for myotonic dystrophy type 1, failed to meet the main goal of a late-stage study, marking its third clinical-trial setback in a week.
EQUITY | Sep 08, 2026, 08:17 AM UTC
M
Novartis shares plunge after trial misses primary goal
Novartis said an experimental neuromuscular medicine missed the primary goal in a late-stage clinical trial. Shares slid 10% shortly after the opening bell Tuesday.
EQUITY | Sep 08, 2026, 08:01 AM UTC
L
Key facts: Novartis (NVS) shares -5% after del-desiran miss; delpacibart gains FDA priority
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
REGULATION | Sep 08, 2026, 07:14 AM UTC
L
Key facts: Novartis posts late-stage failures; keeps 5-6% CAGR
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
EQUITY | Sep 08, 2026, 07:14 AM UTC
M
European shares slip as oil lifts inflation worries; Novartis drags
European stocks edged lower as rising oil prices revived inflation worries and supply concerns tied to a prolonged Middle East conflict. The STOXX 600 fell 0.2% to 648.41. Novartis was under pressure after a second drug
COMMODITIES | Sep 08, 2026, 07:11 AM UTC
M
Novartis del-desiran fails late-stage study in myotonic dystrophy
Novartis said its experimental del-desiran drug for myotonic dystrophy failed in a late-stage study, marking the second pipeline setback in a week.
EQUITY | Sep 08, 2026, 07:03 AM UTC
M
Novartis pipeline setback adds second in a week, Market Talk says
Novartis suffered a second major pipeline setback in a week after acquired drug candidate del-desiran failed in a late-stage study, according to a Vontobel research note cited by Stefan Schneider.
EQUITY | Sep 08, 2026, 06:46 AM UTC
L
Novartis trial setback for del-desiran in myotonic dystrophy study
Novartis said a late-stage study of del-desiran in myotonic dystrophy did not meet a target on a key metric. The company reaffirmed its sales guidance through 2030.
EARNINGS | Sep 08, 2026, 06:03 AM UTC
M
Novartis update: delpacibart etedesiran misses Phase III goal in HARBOR
Novartis provided an update on its delpacibart etedesiran Phase III HARBOR study in myotonic dystrophy type 1 (DM1), saying the neuromuscular drug candidate missed its late-stage trial goal.
EQUITY | Sep 08, 2026, 05:25 AM UTC
L
Novartis Provides Update On Delpacibart Etedesiran (Del-Desiran) Phase Iii Harbor Study
NOVARTIS AG BX:NOT
EQUITY | Sep 08, 2026, 05:05 AM UTC
L
Novartis update on delpacibart etedesiran Phase III HARBOR study
Novartis provided an update on its Phase III HARBOR study of delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1).
EQUITY | Sep 08, 2026, 05:00 AM UTC
H
Novartis slips after pelacarsen Phase 3 setback
Novartis traded at $159.99 after pelacarsen flopped in a pivotal Phase 3 cardiovascular trial. Reuters estimated about CHF4.9 billion evaporated from market value as Zurich-listed shares fell 1.9%.
EQUITY | Sep 07, 2026, 05:56 PM UTC
M
Novartis pelacarsen fails late-stage cholesterol study
Novartis AG says its experimental cholesterol drug pelacarsen failed in a late-stage study, removing an anticipated large prospective medicine-market opportunity.
EQUITY | Sep 07, 2026, 02:46 PM UTC
L
Novartis Heart-Trial Failure Raises Bar for Next Study Results — Market Talk
Novartis's heart-trial failure means investors' attention now shifts to upcoming results from another late-stage study of a drug acquired as part of the company's $12 billion Avidity Biosciences deal, Jefferies analysts
EQUITY | Sep 07, 2026, 09:25 AM UTC
M
Novartis shares slide after heart drug fails late-stage trial target
Novartis said its experimental medicine failed to reduce cardiovascular risk in a late-stage trial, sending shares down 3.2% in European morning trading Monday.
EQUITY | Sep 07, 2026, 08:27 AM UTC
M
Novartis shares fall after cholesterol drug fails in study
Novartis shares fell 3.3% Monday morning after its cholesterol drug pelacarsen failed in a closely watched study, casting doubt on the approach. The failure raises the stakes for upcoming gene-therapy data.
EQUITY | Sep 07, 2026, 08:11 AM UTC
M
Novartis shares drop after cholesterol drug study failure
Novartis shares fell 3.3% Monday morning after its cholesterol drug pelacarsen failed in a closely watched study, increasing pressure on its pipeline and casting new doubt on the approach.
EQUITY | Sep 07, 2026, 07:24 AM UTC
M
Novartis pelacarsen trial miss may be cushioned by investor skepticism
Citi says Novartis’ experimental pelacarsen missed the target in a late-stage clinical trial, but the share-price hit could be mitigated by investor skepticism about the study.
EQUITY | Sep 07, 2026, 07:04 AM UTC
M
Novartis seen facing hit as cholesterol trial fails late-stage endpoint
J.P. Morgan analysts said late-stage results for a cholesterol drug candidate failed to reduce severe cardiovascular events such as heart attacks and strokes, putting pressure on Novartis shares.
EQUITY | Sep 07, 2026, 05:43 AM UTC